A Study in Patients Suffering From Idiopathic Restless Legs Syndrome Who Responded to a Preceding, 6-month Treatment With Open-label Pramipexole Including Titration (0.125, 0.25, 0.5, 0.75 mg Orally q.n.)

Boehringer Ingelheim224 enrolled

Overview

The primary objective is to assess sustained efficacy in patients who have responded to a 6 month treatment with open-label pramipexole. Secondary objectives are the measurement of severity of the RLS, assessment of early withdrawal phenomena after termination of trial medication, augmentation under treatment, sleepiness, quality of life and subjective wellbeing, the physician's clinical assessment of symptom severity and improvement. Another secondary objective is safety and tolerability of treatment.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

224

Conditions

Restless Legs Syndrome

Interventions

Pramipexole

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female out-patients aged 18-80 * Diagnosis of idiopathic RLS according to the Clinical RLS criteria of the International RLS Study Group * RLSRS score \> 15 * RLS symptoms present at least 2 to 3 days per week within the last 3 months * Written informed consent Exclusion Criteria: * Women of childbearing potential without adequate contraception, or breastfeeding * Concomitant or previous pharmacologically therapy of RLS * Clinically significant renal disease, and/or hepatic disease * Any of the following lab results at screening: Hb, TSH, T3 or T4, clinically significantly out of normal range, positive urine drug screen * Other clinically significant metabolic-endocrine (including diabetes mellitus requiring insulin therapy), haematological, gastro-intestinal disease or pulmonary disease . Poorly controlled cardiovascular disease * History or clinical signs of peripheral neuropathy (PNP), myelopathy or multiple sclerosis or any other neurological disease, with potential to secondarily cause RLS symptoms, history of or clinical signs for any form of epilepsy or seizures * Presence of any sleep disorder * History of schizophrenia or any psychotic disorder, history of mental disorders, alcohol abuse or drug addiction * History of or clinical signs of malign neoplasm * Patients on a shift-work-schedule, or who are otherwise unable to follow a regular sleep-wake cycle enabling use of study medication at times indicated * Allergic to pramipexole or its excipients

Locations (12)

Boehringer Ingelheim Investigational Site

Berlin, Germany

Charité Campus Virchow-Klinikum

Berlin, Germany

emovis GmbH

Berlin, Germany

Boehringer Ingelheim Investigational Site

Chemnitz, Germany

ClinPharm Internat. GmbH & Co. KG

Görlitz, Germany

Clinpharm International GmbH & Co. KG

Hellersdorf, Germany

Paracelsus-Elena-Klinik

Kassel, Germany

ClinPharm International GmbH & Co. KG

Leipzig, Germany

Neurologische Klinik der Otto-von-Guericke-Universität

Magdeburg, Germany

Universitätsklinikum Giessen und Marburg

Marburg, Germany

...and 2 more locations

Outcomes

Primary Outcomes

Time to target event (CGI-I rating in association with RLSRS score above 15, period 2) for full analysis set